{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T08:12:49.602911+00:00","company":{"ticker":"COLL","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC"},"pagination":{"limit":100,"returned":42,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Biopharma Credit PLC","detail":"credit_facility","count":1,"first_seen":"2025-12-30T23:59:59+00:00","last_seen":"2025-12-30T23:59:59+00:00","evidence_fact_ids":[36868]},{"display_name":"Hikma Pharmaceuticals USA Inc.","detail":"license","count":1,"first_seen":"2024-04-29T23:59:59+00:00","last_seen":"2024-04-29T23:59:59+00:00","evidence_fact_ids":[57825]},{"display_name":"The Bank of New York Mellon Trust Company, N.A.","detail":"notes_offering","count":1,"first_seen":"2023-02-13T23:59:59+00:00","last_seen":"2023-02-13T23:59:59+00:00","evidence_fact_ids":[179801]},{"display_name":"Truist Bank","detail":"credit_facility","count":1,"first_seen":"2025-12-30T23:59:59+00:00","last_seen":"2025-12-30T23:59:59+00:00","evidence_fact_ids":[36867]}],"lender":[{"display_name":"The Bank of New York Mellon Trust Company, N.A.","detail":"convertible_notes","count":1,"first_seen":"2023-02-13T23:59:59+00:00","last_seen":"2023-02-13T23:59:59+00:00","evidence_fact_ids":[179802]}],"ma_counterparty":[{"display_name":"Corium Therapeutics Holdings, LLC and Corium, LLC","detail":"acquisition","count":1,"first_seen":"2026-05-12T11:43:29+00:00","last_seen":"2026-05-12T11:43:29+00:00","evidence_fact_ids":[54078]},{"display_name":"Ironshore Therapeutics Inc.","detail":"acquisition","count":1,"first_seen":"2024-09-04T23:59:59+00:00","last_seen":"2024-09-04T23:59:59+00:00","evidence_fact_ids":[118005]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"dae54056dde188d734175deeee861181a1857ca1","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-15T20:10:34+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"4,930","votes_against":"252,815","votes_for":"28,953,181","votes_withheld":null}]},"claim":"COLLEGIUM PHARMACEUTICAL, INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.","evidence_excerpt":"PROPOSAL 3 : Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-062536","anchor_url":"https://secwatch.observer/filing/0001104659-26-062536#claim-dae54056dde188d734175deeee861181a1857ca1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926062536/0001104659-26-062536-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7783f24ad50bf6753f8ea0deabc65e5d820db2ab","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-15T20:10:34+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Approval of, on an advisory basis, the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,790,765","subject":null,"votes_abstain":"5,646","votes_against":"1,100,723","votes_for":"26,313,792","votes_withheld":null}]},"claim":"COLLEGIUM PHARMACEUTICAL, INC shareholders approved Approval of, on an advisory basis, the compensation of the Company's named executive officers at the 2026-05-14 meeting.","evidence_excerpt":"PROPOSAL 2: Approval of, on an advisory basis, the compensation of the Company’s named executive officers.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-062536","anchor_url":"https://secwatch.observer/filing/0001104659-26-062536#claim-7783f24ad50bf6753f8ea0deabc65e5d820db2ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926062536/0001104659-26-062536-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0dcb5932bca56b87c690923e0df4a8cdae162375","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-15T20:10:34+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-14","outcome":"passed","proposal_text":"Election of eight Directors to hold office until the 2027 Annual Meeting of Shareholders","proposal_type":"director_election","results":[{"broker_non_votes":"1,790,765","subject":"Rita Balice-Gordon","votes_abstain":"186,467","votes_against":null,"votes_for":"25,890,238","votes_withheld":"1,343,456"},{"broker_non_votes":"1,790,765","subject":"Garen Bohlin","votes_abstain":"82,588","votes_against":null,"votes_for":"27,093,924","votes_withheld":"243,649"},{"broker_non_votes":"1,790,765","subject":"Michael Donovan","votes_abstain":"1,448","votes_against":null,"votes_for":"27,383,194","votes_withheld":"35,519"},{"broker_non_votes":"1,790,765","subject":"John Freund, M.D.","votes_abstain":"2,189","votes_against":null,"votes_for":"26,907,371","votes_withheld":"510,601"},{"broker_non_votes":"1,790,765","subject":"Vikram Karnani","votes_abstain":"2,339","votes_against":null,"votes_for":"27,243,959","votes_withheld":"173,863"},{"broker_non_votes":"1,790,765","subject":"Nancy Lurker","votes_abstain":"746","votes_against":null,"votes_for":"27,379,677","votes_withheld":"39,738"},{"broker_non_votes":"1,790,765","subject":"Carlos Paya, M.D., Ph.D.","votes_abstain":"13,810","votes_against":null,"votes_for":"26,695,542","votes_withheld":"710,809"},{"broker_non_votes":"1,790,765","subject":"Gino Santini","votes_abstain":"2,189","votes_against":null,"votes_for":"26,824,258","votes_withheld":"593,714"}]},"claim":"COLLEGIUM PHARMACEUTICAL, INC shareholders approved Election of eight Directors to hold office until the 2027 Annual Meeting of Shareholders at the 2026-05-14 meeting.","evidence_excerpt":"PROPOSAL 1 : Election of eight Directors to hold office until the 2027 Annual Meeting of Shareholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-062536","anchor_url":"https://secwatch.observer/filing/0001104659-26-062536#claim-0dcb5932bca56b87c690923e0df4a8cdae162375","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926062536/0001104659-26-062536-index.htm"},{"fact_type":"ma_transaction","fact_key":"7adc9670bedc45749a1e4d0f21118415a102efa6","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-12T11:43:29+00:00","payload":{"action":"acquisition","closing_date":"2026-05-12","consideration_text":"approximately $650 million in cash","counterparty":"Corium Therapeutics Holdings, LLC and Corium, LLC","effective_date":"2026-05-12","item_codes_triggered":["2.01"]},"claim":"COLLEGIUM PHARMACEUTICAL, INC completed an acquisition involving Corium Therapeutics Holdings, LLC and Corium, LLC for approximately $650 million in cash (closed 2026-05-12).","evidence_excerpt":"in people 6 years of age and older. The aggregate consideration paid by the Company at the Closing pursuant\nto the Purchase Agreement was approximately $650 million in cash (subject to customary adjustments for net working capital, indebtedness,\ncash, and transaction expenses), which was funded by approximately $350 million of the Company’s","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-26-059018","anchor_url":"https://secwatch.observer/filing/0001104659-26-059018#claim-7adc9670bedc45749a1e4d0f21118415a102efa6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926059018/0001104659-26-059018-index.htm"},{"fact_type":"executive_change","fact_key":"a741068126","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-12T11:43:29+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"termination","effective_date":null,"interim":false,"role":"Executive Vice President and Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Thomas Smith departed as Executive Vice President and Chief Medical Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Thomas Smith, M.D., Executive Vice President and Chief Medical Officer of the Company will depart from his positions at the Company following a transition period during which the Company will conduct a search for his successor.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-059018","anchor_url":"https://secwatch.observer/filing/0001104659-26-059018#claim-a741068126","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926059018/0001104659-26-059018-index.htm"},{"fact_type":"executive_change","fact_key":"f59d2ff804","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-12T11:43:29+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"termination","effective_date":"2026-08-30","interim":false,"role":"Executive Vice President and Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Scott Dreyer departed as Executive Vice President and Chief Commercial Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Scott Dreyer, Executive Vice President and Chief Commercial Officer of the Company will depart from his positions at the Company effective August 30, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-059018","anchor_url":"https://secwatch.observer/filing/0001104659-26-059018#claim-f59d2ff804","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926059018/0001104659-26-059018-index.htm"},{"fact_type":"earnings_release","fact_key":"93bc5cfc037d4ce7edf0c81a9d21c6077bf85777","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$193.5 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2026 results: revenue $193.5 million. Guidance reaffirmed.","evidence_excerpt":"on Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nCollegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress – Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in Second Quarter of","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-26-031694","anchor_url":"https://secwatch.observer/filing/0001628280-26-031694#claim-93bc5cfc037d4ce7edf0c81a9d21c6077bf85777","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000162828026031694/0001628280-26-031694-index.htm"},{"fact_type":"material_agreement","fact_key":"470451fcaf42038a34ec3482b501040a47ac7983","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-12-30T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Second Amended and Restated Loan Agreement","agreement_type":"credit_facility","counterparty":"Biopharma Credit PLC, as collateral agent","effective_date":"2025-12-23","item_codes_triggered":["1.02"],"value_text":null},"claim":"COLLEGIUM PHARMACEUTICAL, INC terminated Second Amended and Restated Loan Agreement with Biopharma Credit PLC, as collateral agent (effective 2025-12-23).","evidence_excerpt":"On December 23, 2025, in connection with its entry into the Credit Agreement, the Company repaid in full all obligations outstanding under the Existing Credit Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-125026","anchor_url":"https://secwatch.observer/filing/0001104659-25-125026#claim-470451fcaf42038a34ec3482b501040a47ac7983","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925125026/0001104659-25-125026-index.htm"},{"fact_type":"material_agreement","fact_key":"45bcc0768fe80fa0f6ad59f0b0dadff76ad249d2","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-12-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Credit Agreement","agreement_type":"credit_facility","counterparty":"Truist Bank, as administrative agent","effective_date":"2025-12-23","item_codes_triggered":["1.01"],"value_text":"$580,000,000 term loan, $300,000,000 of delayed draw term loan commitments, and a $100,000,000 revol"},"claim":"COLLEGIUM PHARMACEUTICAL, INC entered into Credit Agreement with Truist Bank, as administrative agent valued at $580,000,000 term loan, $300,000,000 of delayed draw term loan commitments, and a $100,000,000 revol (effective 2025-12-23).","evidence_excerpt":"On December 23, 2025, Collegium Pharmaceutical, Inc. (the “Company”) entered into a Credit Agreement by and among the Company, the lenders from time to time party thereto and Truist Bank, as administrative agent (the “Credit Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-125026","anchor_url":"https://secwatch.observer/filing/0001104659-25-125026#claim-45bcc0768fe80fa0f6ad59f0b0dadff76ad249d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925125026/0001104659-25-125026-index.htm"},{"fact_type":"executive_change","fact_key":"f5fb1c15ec","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-03-17T23:59:59+00:00","payload":{"action":"named Chairman of the Board","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Gino Santini changed role as Chairman of the Board at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"The Board has named Gino Santini, the Company’s lead independent director since 2018, as Chairman of the Board, effective immediately following the Company’s Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-024185","anchor_url":"https://secwatch.observer/filing/0001104659-25-024185#claim-f5fb1c15ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm"},{"fact_type":"executive_change","fact_key":"9e19e0a311","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-03-17T23:59:59+00:00","payload":{"action":"will not stand for re-election and retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gwen Melincoff departed as Director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Gwen Melincoff also advised the Board that she will not stand for re-election at the Annual Meeting and will retire from the Board at that time.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-024185","anchor_url":"https://secwatch.observer/filing/0001104659-25-024185#claim-9e19e0a311","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm"},{"fact_type":"executive_change","fact_key":"b2f1207de7","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-03-17T23:59:59+00:00","payload":{"action":"will not stand for re-election and retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Gino Santini","successor_named":true},"claim":"Michael Heffernan departed as Chairman of the Board at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Michael Heffernan, R.Ph., founder and current Chairman of the Board advised the Board that he will not stand for re-election at the Annual Meeting and will retire from the Board at that time.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-024185","anchor_url":"https://secwatch.observer/filing/0001104659-25-024185#claim-b2f1207de7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm"},{"fact_type":"executive_change","fact_key":"513ca5e21d","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-03-17T23:59:59+00:00","payload":{"action":"nominated","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Carlos Paya was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"approved the nomination of Dr. Carlos Paya to stand for election","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-024185","anchor_url":"https://secwatch.observer/filing/0001104659-25-024185#claim-513ca5e21d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm"},{"fact_type":"executive_change","fact_key":"fcab5da270","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-02-27T23:59:59+00:00","payload":{"action":"stepping down","action_category":"departure","departure_tone":"termination","effective_date":"2025-03-07","interim":false,"role":"Executive Vice President, Chief Administrative Officer, General Counsel & Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Shirley Kuhlmann departed as Executive Vice President, Chief Administrative Officer, General Counsel & Secretary at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On February 27, 2025, the Company announced that Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel & Secretary of the Company will step down from her positions at the Company effective March 7, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001799","anchor_url":"https://secwatch.observer/filing/0001558370-25-001799#claim-fcab5da270","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025001799/0001558370-25-001799-index.htm"},{"fact_type":"executive_change","fact_key":"3e36ada91e","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-02-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Nancy Lurker was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-25-009384","anchor_url":"https://secwatch.observer/filing/0001104659-25-009384#claim-3e36ada91e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/0001104659-25-009384-index.htm"},{"fact_type":"executive_change","fact_key":"cfc4a15cc5","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-11-07T23:59:59+00:00","payload":{"action":"succeeded","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-11-12","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Vikram Karnani","successor_named":true},"claim":"Michael Heffernan changed role as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"succeeding Michael Heffernan, who will continue to serve as the Company’s Chairman of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-115287","anchor_url":"https://secwatch.observer/filing/0001104659-24-115287#claim-cfc4a15cc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm"},{"fact_type":"executive_change","fact_key":"abc93d740f","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-11-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-12","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vikram Karnani was appointed as member of the Board at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-115287","anchor_url":"https://secwatch.observer/filing/0001104659-24-115287#claim-abc93d740f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm"},{"fact_type":"executive_change","fact_key":"72bed20dc9","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-11-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-12","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Vikram Karnani was appointed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"the Board of Directors (the “Board”) of the Company appointed Vikram Karnani to serve as the Company’s President and Chief Executive Officer, effective November 12, 2024","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-115287","anchor_url":"https://secwatch.observer/filing/0001104659-24-115287#claim-72bed20dc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm"},{"fact_type":"ma_transaction","fact_key":"8915333e827007c5be81a27bd81c9d59030092c2","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-09-03","consideration_text":"approximately $525 million in cash","counterparty":"Ironshore Therapeutics Inc.","effective_date":"2024-09-03","item_codes_triggered":["2.01"]},"claim":"COLLEGIUM PHARMACEUTICAL, INC completed an acquisition involving Ironshore Therapeutics Inc. for approximately $525 million in cash (closed 2024-09-03).","evidence_excerpt":"The aggregate consideration paid by the Company at the Closing pursuant to the Merger Agreement was approximately $525 million in cash (subject to customary adjustments for net working capital, indebtedness, cash, and transaction expenses), with one potential future commercial milestone payment of $25 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-096647","anchor_url":"https://secwatch.observer/filing/0001104659-24-096647#claim-8915333e827007c5be81a27bd81c9d59030092c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924096647/0001104659-24-096647-index.htm"},{"fact_type":"executive_change","fact_key":"4bc9b429e5","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-07-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-28","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Neil McFarlane resigned as director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On July 28, 2024, Neil McFarlane notified the board of directors of the Company (the “Board”) of his intent to resign from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-083126","anchor_url":"https://secwatch.observer/filing/0001104659-24-083126#claim-4bc9b429e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/0001104659-24-083126-index.htm"},{"fact_type":"executive_change","fact_key":"f91689985a","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-24T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-24","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Michael Heffernan","successor_named":true},"claim":"Joseph Ciaffoni departed as Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Also on May 24, 2024, the Company entered into a Separation and Release Agreement with Mr. Ciaffoni (the “Separation Agreement”) in connection with his previously announced departure from the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-065119","anchor_url":"https://secwatch.observer/filing/0001104659-24-065119#claim-f91689985a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm"},{"fact_type":"executive_change","fact_key":"7ef891ba2b","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-24","interim":true,"role":"Interim President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On May 24, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Michael Heffernan in connection with Mr. Heffernan’s appointment as Interim President and Chief Executive Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-065119","anchor_url":"https://secwatch.observer/filing/0001104659-24-065119#claim-7ef891ba2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm"},{"fact_type":"executive_change","fact_key":"5ff41eadeb","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-24","interim":true,"role":"Interim President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"the Board approved the appointment of Michael Heffernan, the Company’s Chairman of the Board, to Interim President and Chief Executive Officer, effective May 24, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059656","anchor_url":"https://secwatch.observer/filing/0001104659-24-059656#claim-5ff41eadeb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm"},{"fact_type":"executive_change","fact_key":"141515a7a8","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-10T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-24","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Michael Heffernan","successor_named":true},"claim":"Joseph Ciaffoni departed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"announced that Joseph Ciaffoni will step down as the President and Chief Executive Officer of Collegium Pharmaceutical, Inc. (the “Company”) effective May 24, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059656","anchor_url":"https://secwatch.observer/filing/0001104659-24-059656#claim-141515a7a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm"},{"fact_type":"earnings_release","fact_key":"ebc2e215a3343d1ffe7bf859b439895362490584","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$27.7 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$144.9 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2024 results: revenue $144.9 million, net income $27.7 million, EPS $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted). Guidance reaffirmed.","evidence_excerpt":"under Item 2.02 of this Current Report on Form 8-K. ​ \n\n--- EX-99.1 (EX-99.1) ---\n\n​ Collegium Reports First Quarter 2024 Financial Results ​ – Generated Q1’24 Net Revenue of $144.9 Million – ​ – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – ​ – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-007596","anchor_url":"https://secwatch.observer/filing/0001558370-24-007596#claim-ebc2e215a3343d1ffe7bf859b439895362490584","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/0001558370-24-007596-index.htm"},{"fact_type":"material_agreement","fact_key":"41de2d0a68abb74ebfd07a33b9875b5ee2e5efdb","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Authorized Generic Agreement","agreement_type":"license","counterparty":"Hikma Pharmaceuticals USA Inc.","effective_date":"2024-04-26","item_codes_triggered":["1.01"],"value_text":null},"claim":"COLLEGIUM PHARMACEUTICAL, INC entered into Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. (effective 2024-04-26).","evidence_excerpt":"On April 26, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into an Authorized Generic Agreement (the “AG Agreement”) with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which the Company granted to Hikma certain rights relating to an authorized generic version of the Company’s Nucynta IR product (the “Nucynta IR Authorized Generic”) and the Company’s Nucynta ER product (the “Nucynta ER Authorized Generic” and, collectively, the “Nucynta AG Products”) in the United States.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-053506","anchor_url":"https://secwatch.observer/filing/0001104659-24-053506#claim-41de2d0a68abb74ebfd07a33b9875b5ee2e5efdb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924053506/0001104659-24-053506-index.htm"},{"fact_type":"earnings_release","fact_key":"41c913d3bca21d8a7fa36bea1d0506ff9731e9e3","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":"$0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted); $1.43 GAAP earnings per share (basic)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$31.9 Million and $48.2 Million","period_text":"the quarterly period and fiscal year ended December 31, 2023","report_date":"2024-02-22","result_type":"reported_results","revenue_text":"$149.7 Million and $566.8 Million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarterly period and fiscal year ended December 31, 2023 results: revenue $149.7 Million and $566.8 Million, net income $31.9 Million and $48.2 Million, EPS $0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted); $1.43 GAAP earnings per share (basic). Guidance reaffirmed.","evidence_excerpt":"8-K. ​ \n\n--- EX-99.1 (EX-99.1) ---\n\n​ Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results ​ – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – ​ – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – ​ – Delivered Record Quarterly and Full-Year Adjusted EBITDA of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-001524","anchor_url":"https://secwatch.observer/filing/0001558370-24-001524#claim-41c913d3bca21d8a7fa36bea1d0506ff9731e9e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024001524/0001558370-24-001524-index.htm"},{"fact_type":"earnings_release","fact_key":"76a72acbca10b0eb4ec14ab5ce20cecaca6deb2c","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":"$0.61 GAAP earnings per share (basic) and $0.53 GAAP earnings per share (diluted)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$20.6 million","period_text":"the quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":"$136.7 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended September 30, 2023 results: revenue $136.7 million, net income $20.6 million, EPS $0.61 GAAP earnings per share (basic) and $0.53 GAAP earnings per share (diluted). Guidance reaffirmed.","evidence_excerpt":"not filed, under Item 2.02 of this Current Report on Form 8-K. ​ \n\n--- EX-99.1 (EX-99.1) ---\n\n​ Collegium Reports Third Quarter 2023 Financial Results ​ – Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – ​ – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – ​ – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19%","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-017980","anchor_url":"https://secwatch.observer/filing/0001558370-23-017980#claim-76a72acbca10b0eb4ec14ab5ce20cecaca6deb2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023017980/0001558370-23-017980-index.htm"},{"fact_type":"earnings_release","fact_key":"dfcffe89aac67e90518b0ca8cd6282f175f4cfd1","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-08-03T23:59:59+00:00","payload":{"eps_text":"$0.34 GAAP earnings per share (diluted)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$13.0 million","period_text":"quarter ended June 30, 2023","report_date":"2023-08-03","result_type":"reported_results","revenue_text":"$135.5 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported quarter ended June 30, 2023 results: revenue $135.5 million, net income $13.0 million, EPS $0.34 GAAP earnings per share (diluted). Guidance reaffirmed.","evidence_excerpt":"of this Current Report on Form 8-K. ​ \n\n--- EX-99.1 (EX-99.1) ---\n\n​ Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year ​ – Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – ​ – Q2’23 GAAP Net Income of $13.0 Million – ​ – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – ​ – Board of Directors has Authorized","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-013191","anchor_url":"https://secwatch.observer/filing/0001558370-23-013191#claim-dfcffe89aac67e90518b0ca8cd6282f175f4cfd1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/0001558370-23-013191-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e6cd91ddea597df1c48c0eab0b8fe46cb29497be","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":null,"votes_against":"44,006","votes_for":"30,742,534","votes_withheld":null}]},"claim":"COLLEGIUM PHARMACEUTICAL, INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_excerpt":"Proposal 3 was approved by the Company's shareholders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-062681","anchor_url":"https://secwatch.observer/filing/0001104659-23-062681#claim-e6cd91ddea597df1c48c0eab0b8fe46cb29497be","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923062681/0001104659-23-062681-index.htm"},{"fact_type":"shareholder_vote","fact_key":"31f1e40188b3398c535d2ef5c44e91acf046b068","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of, on an advisory basis, the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,455,884","subject":null,"votes_abstain":"90,502","votes_against":"315,383","votes_for":"27,953,926","votes_withheld":null}]},"claim":"COLLEGIUM PHARMACEUTICAL, INC shareholders approved Approval of, on an advisory basis, the compensation of the Company's named executive officers.","evidence_excerpt":"On an advisory basis, the Company's shareholders approved the compensation of the Company's named executive officers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-062681","anchor_url":"https://secwatch.observer/filing/0001104659-23-062681#claim-31f1e40188b3398c535d2ef5c44e91acf046b068","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923062681/0001104659-23-062681-index.htm"},{"fact_type":"shareholder_vote","fact_key":"17b9ebef7f415172c69af520c5740726818d1820","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of nine Directors to hold office until the 2024 Annual Meeting of Shareholders","proposal_type":"director_election","results":[{"broker_non_votes":"2,455,884","subject":"Rita Balice-Gordon","votes_abstain":null,"votes_against":null,"votes_for":"28,110,968","votes_withheld":"228,126"},{"broker_non_votes":"2,455,884","subject":"Garen Bohlin","votes_abstain":null,"votes_against":null,"votes_for":"28,254,994","votes_withheld":"83,040"},{"broker_non_votes":"2,455,884","subject":"Joseph Ciaffoni","votes_abstain":null,"votes_against":null,"votes_for":"28,252,708","votes_withheld":"86,385"},{"broker_non_votes":"2,455,884","subject":"John Fallon","votes_abstain":null,"votes_against":null,"votes_for":"25,876,429","votes_withheld":"2,462,321"},{"broker_non_votes":"2,455,884","subject":"John Freund","votes_abstain":null,"votes_against":null,"votes_for":"28,244,410","votes_withheld":"94,340"},{"broker_non_votes":"2,455,884","subject":"Michael Heffernan","votes_abstain":null,"votes_against":null,"votes_for":"26,667,450","votes_withheld":"1,671,643"},{"broker_non_votes":"2,455,884","subject":"Neil McFarlane","votes_abstain":null,"votes_against":null,"votes_for":"28,255,598","votes_withheld":"83,495"},{"broker_non_votes":"2,455,884","subject":"Gwen Melincoff","votes_abstain":null,"votes_against":null,"votes_for":"27,982,535","votes_withheld":"353,536"},{"broker_non_votes":"2,455,884","subject":"Gino Santini","votes_abstain":null,"votes_against":null,"votes_for":"28,128,667","votes_withheld":"210,074"}]},"claim":"COLLEGIUM PHARMACEUTICAL, INC shareholders approved Election of nine Directors to hold office until the 2024 Annual Meeting of Shareholders.","evidence_excerpt":"Each of Rita Balice-Gordon, Garen Bohlin, Joseph Ciaffoni, John Fallon, John Freund, Michael Heffernan, Neil F. McFarlane, Gwen Melincoff, and Gino Santini was re-elected by the Company's shareholders as Directors to hold office until the 2024 Annual Meeting of Shareholders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-062681","anchor_url":"https://secwatch.observer/filing/0001104659-23-062681#claim-17b9ebef7f415172c69af520c5740726818d1820","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923062681/0001104659-23-062681-index.htm"},{"fact_type":"earnings_release","fact_key":"2063171073c9aa61dd1533ac802db291f01ede7a","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full Year 2023","report_date":"2023-05-04","result_type":"guidance_update","revenue_text":"$565.0 to $580.0 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported Full Year 2023 results: revenue $565.0 to $580.0 million. Guidance reaffirmed.","evidence_excerpt":"The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA: ​ Product Revenues, Net $565.0 to $580.0 million Adjusted Operating Expenses (Excluding Stock-Based Compensation) $135.0 to $145.0 million Adjusted EBITDA (Excluding Stock-Based Compensation) $355.0 to $370.0 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-008080","anchor_url":"https://secwatch.observer/filing/0001558370-23-008080#claim-2063171073c9aa61dd1533ac802db291f01ede7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/0001558370-23-008080-index.htm"},{"fact_type":"earnings_release","fact_key":"a9dcfa27268f46e6ed210d66ab26fb83d5883d57","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":"$(0.74) GAAP loss per share (basic and diluted)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(25.0) million","period_text":"the year ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$463.9 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the year ended December 31, 2022 results: revenue $463.9 million, net income $(25.0) million, EPS $(0.74) GAAP loss per share (basic and diluted). Guidance reaffirmed.","evidence_excerpt":"● Product revenues, net were $463.9 million for the year ended December 31, 2022 (“FY 2022”), compared to $276.9 million for the year ended December 31, 2021 (“FY 2021”). ● GAAP operating expenses were $176.2 million for FY 2022, compared to $133.0 million for FY 2021. Adjusted operating expenses, which exclude stock-based compensation of $22.9 million and acquisition related expenses of $31.3 million, were $122.0 million for FY 2022, compared to $101.2 million for FY 2021, which excluded stock-based compensation expense of $24.3 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for FY 2022 was $(25.0) million, with $(0.74) GAAP loss per share (basic and diluted), compared to GAAP net income for FY 2021 of $71.5 million, with $2.05 GAAP earnings per share (basic) and $1.86 GAAP earnings per share (diluted).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-001897","anchor_url":"https://secwatch.observer/filing/0001558370-23-001897#claim-a9dcfa27268f46e6ed210d66ab26fb83d5883d57","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm"},{"fact_type":"earnings_release","fact_key":"878c32a3bec10ce9641c6445eb62b27800c8b2bd","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":"$(0.21) GAAP loss per share (basic and diluted)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(7.2) million","period_text":"the quarter ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$129.6 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended December 31, 2022 results: revenue $129.6 million, net income $(7.2) million, EPS $(0.21) GAAP loss per share (basic and diluted). Guidance reaffirmed.","evidence_excerpt":"● Product revenues, net were $129.6 million for the quarter ended December 31, 2022 (the “2022 Quarter”), compared to $27.4 million for the quarter ended December 31, 2021 (the “2021 Quarter”). ● GAAP operating expenses were $38.0 million for the 2022 Quarter, compared to $32.8 million for the 2021 Quarter. Adjusted operating expenses, which exclude stock-based compensation expense of $5.7 million and acquisition related expenses of $0.1 million, were $32.3 million for the 2022 Quarter, compared to $20.4 million for the 2021 Quarter, which excluded stock-based compensation expense of $4.9 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for the 2022 Quarter was $(7.2) million, with $(0.21) GAAP loss per share (basic and diluted), compared to GAAP net loss for the 2021 Quarter of $(25.0) million, with $(0.73) GAAP loss per share (basic and diluted).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-001897","anchor_url":"https://secwatch.observer/filing/0001558370-23-001897#claim-878c32a3bec10ce9641c6445eb62b27800c8b2bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm"},{"fact_type":"debt_financing","fact_key":"b87a49929a45929831c2d558445ea4f30ed996a1","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-13T23:59:59+00:00","payload":{"counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2023-02-10","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"2.875% per annum","item_codes_triggered":["2.03"],"maturity_text":"February 15, 2029","principal_text":"$241,500,000 principal amount"},"claim":"COLLEGIUM PHARMACEUTICAL, INC incurred convertible notes of $241,500,000 principal amount with The Bank of New York Mellon Trust Company, N.A. at 2.875% per annum maturing February 15, 2029.","evidence_excerpt":"On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-019671","anchor_url":"https://secwatch.observer/filing/0001104659-23-019671#claim-b87a49929a45929831c2d558445ea4f30ed996a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm"},{"fact_type":"material_agreement","fact_key":"5e079cba06b28ee366cf7d1d846d930ff5ff5c85","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"2.875% Convertible Senior Notes due 2029 Indenture","agreement_type":"notes_offering","counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2023-02-10","item_codes_triggered":["1.01"],"value_text":"$241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029"},"claim":"COLLEGIUM PHARMACEUTICAL, INC entered into 2.875% Convertible Senior Notes due 2029 Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029 (effective 2023-02-10).","evidence_excerpt":"On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of February 10, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “ Trustee ”).","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001104659-23-019671","anchor_url":"https://secwatch.observer/filing/0001104659-23-019671#claim-5e079cba06b28ee366cf7d1d846d930ff5ff5c85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm"},{"fact_type":"earnings_release","fact_key":"00c1d51e155d94da33e7283680ad6441f49ed37e","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2022","report_date":"2023-02-06","result_type":"preliminary_results","revenue_text":"$460.0 million to $462.5 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the fiscal year ended December 31, 2022 results: revenue $460.0 million to $462.5 million.","evidence_excerpt":"For the fiscal year ended December 31, 2022, we currently estimate: o Product revenues in the range of $460.0 million to $462.5 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-011184","anchor_url":"https://secwatch.observer/filing/0001104659-23-011184#claim-00c1d51e155d94da33e7283680ad6441f49ed37e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm"},{"fact_type":"earnings_release","fact_key":"02b69c3c39817bf6a45e50dcd14fa14b91b65764","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-02-06","result_type":"preliminary_results","revenue_text":"$125.7 million to $128.2 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported the fourth quarter ended December 31, 2022 results: revenue $125.7 million to $128.2 million.","evidence_excerpt":"For the fourth quarter ended December 31, 2022, we currently estimate: o Product revenues in the range of $125.7 million to $128.2 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-011184","anchor_url":"https://secwatch.observer/filing/0001104659-23-011184#claim-02b69c3c39817bf6a45e50dcd14fa14b91b65764","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm"},{"fact_type":"earnings_release","fact_key":"81f64d0b87062bacdc6a0248189dd8910430fb6c","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2022-11-03T23:59:59+00:00","payload":{"eps_text":"0.01","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"0.5 million","period_text":"quarter ended September 30, 2022","report_date":"2022-11-03","result_type":"reported_results","revenue_text":"127.0 million"},"claim":"COLLEGIUM PHARMACEUTICAL, INC reported quarter ended September 30, 2022 results: revenue 127.0 million, net income 0.5 million, EPS 0.01.","evidence_excerpt":"Total net product revenues were $127.0 million for the quarter ended September 30, 2022 (the “2022 Quarter”), compared to $78.8 million for the quarter ended September 30, 2021 (the “2021 Quarter”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-016231","anchor_url":"https://secwatch.observer/filing/0001558370-22-016231#claim-81f64d0b87062bacdc6a0248189dd8910430fb6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/0001558370-22-016231-index.htm"},{"fact_type":"executive_change","fact_key":"5d209e23cf","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2022-04-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-04-06","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Neil F. McFarlane was appointed as director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On April 6, 2022, the Board of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from eight to nine members and appointed Mr. Neil F. McFarlane, 49, as a director of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-043015","anchor_url":"https://secwatch.observer/filing/0001104659-22-043015#claim-5d209e23cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465922043015/0001104659-22-043015-index.htm"},{"fact_type":"executive_change","fact_key":"2d15da3b87","cik":1267565,"ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2021-09-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-09-30","interim":false,"role":"Executive Vice President and Chief Technical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Alison Fleming resigned as Executive Vice President and Chief Technical Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On September 24, 2021, Dr. Alison Fleming resigned from her positions as Executive Vice President and Chief Technical Officer of Collegium Pharmaceutical, Inc. (the “ Company ”), effective September 30, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-21-121292","anchor_url":"https://secwatch.observer/filing/0001104659-21-121292#claim-2d15da3b87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465921121292/0001104659-21-121292-index.htm"}]}